Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.43 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.43 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.43 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559702 | 0.98 | MAOA (0.52) | MAOAMAOBNPC1RAB9APTPRA | |
| SCHEMBL9491676 | 0.81 | KDM4E (0.63) | MAOAMAOBPTPRAKDM4EGRIN2D | |
| SCHEMBL22728750 | 0.81 | KDM4E (0.63) | MAOAMAOBPTPRAKDM4EGRIN2D | |
| SCHEMBL27701885 | 0.80 | MAOA (0.49) | MAOAMAOBNPC1RAB9APTPRA | |
| SCHEMBL5949509 | 0.78 | IGF1R (0.50) | PTPRAKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5949323 | 0.78 | IGF1R (0.50) | PTPRAKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5948990 | 0.78 | IGF1R (0.50) | PTPRAKDM4EGRIN2DGRIN3BGRIN1 | |
| SCHEMBL5949524 | 0.78 | PTPRA (0.46) | NPC1RAB9APTPRAKDM4EGRIN2D | |
| SCHEMBL11084913 | 0.78 | MEN1 (0.50) | NPC1RAB9APTPRAKDM4EGRIN2D | |
| SCHEMBL27701887 | 0.77 | MAOA (0.49) | MAOAMAOBNPC1RAB9APTPRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211731-A1 | New substituted pyridine or piperidine compounds | LES LABORATORIES SERVIER (FR) | 2006-09-21 | — | — | US | disclosed |
| US-20050004168-A1 | New substituted pyridine or piperidine compounds | METH-COHN OTTO (GB) | 2005-01-06 | — | — | US | disclosed |
| US-6734196-B2 | ANALGESICS; COGNITION ACTIVATORS | LES LABORATOIRES SERVIER (FR) | 2004-05-11 | — | — | US | disclosed |
| US-6638946-B2 | 1-(4-bromophenyl)-2-(1-methyl-2-piperidinyl)-1-ethanone, for example; treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Korsakoff's disease and frontal lobe and subcortical dementias | LES LABORATOIRES SERVIER (FR) | 2003-10-28 | — | — | US | disclosed |
| US-20030181484-A1 | New substituted pyridine or piperidine compounds | METH-COHN OTTO (GB) | 2003-09-25 | — | — | US | disclosed |
| US-20030139408-A1 | Substituted pyridine or piperidine compounds | METH-COHN OTTO (GB) | 2003-07-24 | — | — | US | disclosed |
| US-6511992-B2 | For treating pain or memory deficiencies related to Alzheimer's disease and other neurodegenerative disorders associated with aging | LES LABORATORIES SERVIER (FR) | 2003-01-28 | — | — | US | disclosed |
| US-20020040036-A1 | New substituted pyridine or piperidine compounds | ADIR ET COMPAGNIE | 2002-04-04 | — | — | US | disclosed |
| US-20020035123-A1 | New substituted pyridine or piperidine compounds | ADIR ET COMPAGNIE | 2002-03-21 | — | — | US | disclosed |
| US-6323220-B1 | COGNITION ACTIVATORS AND TREATMENT OF NERVOUS SYSTEM DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181484-A1 | New substituted pyridine or piperidine compounds | CNR1, HRH4, OPRD1 | MAOA 2811/4885MAOB 1898/4885NPC1 2461/4885 |
| US-20060211731-A1 | New substituted pyridine or piperidine compounds | HRH3, P2RY1, CHRM1 | MAOA 2864/4885MAOB 1909/4885NPC1 2862/4885 |
| US-20030139408-A1 | Substituted pyridine or piperidine compounds | P2RY1, HRH3, CNR1 | MAOA 2854/4885MAOB 1954/4885NPC1 2338/4885 |
| US-20050004168-A1 | New substituted pyridine or piperidine compounds | HRH3, HRH4, HRH1 | MAOA 2417/4885MAOB 1496/4885NPC1 2766/4885 |
| US-20020035123-A1 | New substituted pyridine or piperidine compounds | OPRD1, CNR1, HRH4 | MAOA 2965/4885MAOB 2024/4885NPC1 2642/4885 |
| US-20020040036-A1 | New substituted pyridine or piperidine compounds | CNR1, OPRD1, OPRK1 | MAOA 2650/4885MAOB 1736/4885NPC1 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.